Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERACT stomach-II
2025-521468-36-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in gastric cancer (GC), gastroesophageal junction adenocarcinoma and peritoneal carcinomatosis (PC), sponsored by Erasmus MC. Primary endpoint: Feasibility of combined intraperitoneal irinotecan and systemic therapy. Planned start Sep 2025; status: authorised.
02
Drugs
irinotecan
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on 2025-521468-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521468-36-00.